Bicara Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.6%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$3.40next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly539.8MTarget: Sufficient to fund operations into the first half of 2029
FORTIFI-HN01 Phase 3 Enrollment Progress AnnuallyTarget: Substantially enrolled by the end of 2026 to enable interim analysis in mid-2027
Ficerafusp Alfa Confirmed Objective Response Rate (ORR) at 1500mg QW Annually54.0%Target: Maintain superior efficacy profile compared to pembrolizumab monotherapy (~19%)
Watch Items
- Initiation of randomized loading/maintenance dosing study for ficerafusp alfaTrigger: Study initiation scheduled for Q3 2026Action: Monitor clinical trial registry updates and company press releases for first patient dosed
- Phase 1b expansion cohort data readout for 3L+ mCRC (colorectal cancer)Trigger: Data presentation scheduled for 2H 2026Action: Evaluate signal-seeking efficacy and safety data to assess pipeline expansion potential beyond HNSCC
- Interim analysis readout of the pivotal FORTIFI-HN01 Phase 2/3 trialTrigger: Expected in mid-2027Action: Review efficacy and safety endpoints to support potential accelerated FDA approval filing
Research as of 19 Jun 2026